Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the second quarter — with an asterisk shaped like the novel coronavirus.
You may have heard something about a global, all-hands push to develop new medicines to treat Covid-19. This work will extend way beyond the second quarter, but the first (and therefore most highly anticipated) effort is expected to read out Phase 3 results in the next few weeks. All eyes will be on Gilead Sciences, which hopes to show that intravenously infused doses of the antiviral drug remdesivir are safe for patients and effective against Covid-19.
It’s also possible by late in the second quarter that Moderna and its partner, the National Institutes of Health, will present the first look at safety data on an mRNA-based vaccine against the novel coronavirus.
About the Author Reprints
